Risk-adapted radiotherapy in pediatric neuroblastoma: current evidence, controversies, and future directions-a narrative review.
- 1Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
Radiotherapy is an established component of treatment for high-risk neuroblastoma, but questions remain about dose escalation, target definition, and the selection of metastatic sites for irradiation. This narrative review examines the evidence informing radiotherapy decisions in children with neuroblastoma, with particular attention to local control, normal-tissue exposure, and late toxicity. A targeted PubMed search covered English-language publications from database inception. The initial search was conducted on 30 June 2026 and updated on 11 August 2026. Topic-specific free-text searches addressed radiotherapy, metastatic disease, treatment techniques, molecular imaging, artificial intelligence (AI), and toxicity. Reference lists, cooperative-group reports, and guidelines provided additional sources. Studies were selected for their relevance to radiotherapy decisions. Evidence supports consolidative primary-site radiotherapy in high-risk neuroblastoma. The Children's Oncology Group ANBL0532 study prescribed 21.6 Gy to the post-induction/preoperative primary tumor volume; a boost to postoperative gross residual disease did not significantly improve local control relative to a historical comparator. Metastasis-directed radiotherapy may be appropriate for selected residual, symptomatic, or anatomically high-risk lesions, but routine treatment of every initially involved metastatic site is not supported. Elective nodal irradiation is also not routinely indicated. Proton therapy, intraoperative radiotherapy (IORT), and advanced imaging have potential roles in selected patients, although their evidence bases differ and comparative outcome data remain limited. Radiotherapy decisions should reflect the clinical setting, response to systemic treatment, residual disease, and expected toxicity. Better reporting of target volumes, dose-volume parameters, imaging response, and long-term outcomes is needed to define which patients benefit from treatment intensification or reduction.
Related
- Diagnostic potential of Aldo-keto reductase 1B10 in pediatric hepatic malignancies: a narrative, hypothesis-generating translational review based on adult evidence and future research directions
- Machine learning prediction model for distant metastasis at diagnosis in pediatric neuroblastoma: development, interpretation, and temporal validation
- Molecular, Cytogenetic, and Immunophenotypic Biomarkers in Acute Myeloid Leukemia: Current Evidence and Future Directions—A Narrative Review
- Scabies Diagnosis: A Narrative Review of Diagnostic Methods, Clinical Misdiagnosis, and Emerging Directions
- Mechanical circulatory support devices in heart failure: a narrative review of current evidence, clinical applications, complications, and future directions
BibTeX
@article{yu2026riskadapted,
title = {{Risk-adapted radiotherapy in pediatric neuroblastoma: current evidence, controversies, and future directions-a narrative review.}},
author = {Linxi Yu and Hui Guan and Zhikai Liu},
journal = {Translational pediatrics},
year = {2026},
month = oct,
doi = {10.21037/tp-2026-0673},
url = {https://europepmc.org/article/MED/42996725},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Risk-adapted radiotherapy in pediatric neuroblastoma: current evidence, controversies, and future directions-a narrative review.
AU - Linxi Yu
AU - Hui Guan
AU - Zhikai Liu
PY - 2026
DA - 2026/10/15
JO - Translational pediatrics
DO - 10.21037/tp-2026-0673
UR - https://europepmc.org/article/MED/42996725
AB - Radiotherapy is an established component of treatment for high-risk neuroblastoma, but questions remain about dose escalation, target definition, and the selection of metastatic sites for irradiation. This narrative review examines the evidence informing radiotherapy decisions in children with neuroblastoma, with particular attention to local control, normal-tissue exposure, and late toxicity. A targeted PubMed search covered English-language publications from database inception. The initial search was conducted on 30 June 2026 and updated on 11 August 2026. Topic-specific free-text searches addressed radiotherapy, metastatic disease, treatment techniques, molecular imaging, artificial intelligence (AI), and toxicity. Reference lists, cooperative-group reports, and guidelines provided additional sources. Studies were selected for their relevance to radiotherapy decisions. Evidence supports consolidative primary-site radiotherapy in high-risk neuroblastoma. The Children's Oncology Group ANBL0532 study prescribed 21.6 Gy to the post-induction/preoperative primary tumor volume; a boost to postoperative gross residual disease did not significantly improve local control relative to a historical comparator. Metastasis-directed radiotherapy may be appropriate for selected residual, symptomatic, or anatomically high-risk lesions, but routine treatment of every initially involved metastatic site is not supported. Elective nodal irradiation is also not routinely indicated. Proton therapy, intraoperative radiotherapy (IORT), and advanced imaging have potential roles in selected patients, although their evidence bases differ and comparative outcome data remain limited. Radiotherapy decisions should reflect the clinical setting, response to systemic treatment, residual disease, and expected toxicity. Better reporting of target volumes, dose-volume parameters, imaging response, and long-term outcomes is needed to define which patients benefit from treatment intensification or reduction.
SN - 2224-4336
SN - 2224-4344
ER -